Clinical trial NCT00236210: A Randomized Controlled Trial of a Novel Community-based Primary and Secondary Cardiovascular Prevention Program
Official title: The Vascular Intervention Project (VIP): a Randomized Controlled Trial of a Novel Community-based Primary and Secondary Cardiovascular Prevention Program in the Algoma District of Northern Ontario
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Vascular Disease
Diabetes
Hypertension
Hyperlipidemia
Obesity
Keywords: Vascular Intervention Program
Vascular Disease
Coronary Artery Disease
Diabetes
Lifestyle Modification
Modifiable Risk Factors
Lead sponsor: Group Health Centre
Sponsor class: OTHER
Collaborators: name: Ontario Ministry of Health and Long Term Care
name: McMaster University
name: Coalition for the Acquisition of Sound Habits
name: Ministry of Northern Development and Mines Youth Internship Program
name: Pfizer
First posted: 2005-10-12
Enrollment: 422
Sex: ALL
Minimum age (years): 30
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: VIP is a demonstration project with a goal to decrease modifiable risk factors for those with a higher risk of having a vascular event such as a heart attack or stroke or of developing vascular disease. Introduced as a study, VIP compares whether there is a significant reduction of modifiable vascular risk factors among patients who are involved in a personalized directed program versus those being provided standard care by their physician. Health care providers work collaboratively with the 'VIP Team' to improve the participants' vascular health.

Detailed description: This Northern Ontario, community-based demonstration project is a multi-disciplinary, primary care provider-based collaboration. The goals of the project are to:

1. Decrease the modifiable risk factors for primary care patients at risk for vascular disease in the Algoma District;
2. Increase collaboration between health care providers such as family physicians, pharmacists, physiotherapists, dietitians and nurses in the community;
3. Increase the participation of the patient and family in decision-making, self-care, and adherence to agreed-upon management plans;
4. Improve patient access to care, clinical outcomes and satisfaction;
5. Provide a business case for a practical, sustainable and generalizable model for the primary care of vascular disease in the community.

The Group Health Centre, a multi-disciplinary, not-for-profit community-based health organization with 56,000 rostered patients, leads the project. However, all Sault Ste Marie community patients are eligible to join the Vascular Intervention Program (VIP). This program has three key components: a registry of VIP patients with audit, recall and feedback; use of the novel ACTION score template, and the optional use of VIPNet, a personalized patient record tool that provides secure web access to optimize quality and continuity of care. The VIP project aims to empower patients and increase collaboration among the primary health care team. Patients with any vascular risk factors will be eligible for VIP.

The VIP project is a demonstration project that does not duplicate existing GHC chronic disease management programs because (1) the VIP is offered to all eligible community patients, not only GHC enrollees; (2) VIP integrates any patients with vascular risk, not just those with pre-defined conditions; (3) novel collaborative tools such as the ACTION template and VIPNet website are being piloted; and (4) explicit patient-centred decision making drives the process. The development and evaluation of the VIP demonstration project is a unique step in the evolution of primary care chronic disease management in Sault Ste Marie, and the rest of the province.

Eligibility criteria: Inclusion Criteria:

* Men \>30 years of age
* Women \> 40 years of age
* History of vascular disease (as defined in Study Design, page 8)
* Framingham Risk Score \>/= 12 %
* Capable of giving informed consent
* Ability and willingness to complete questionnaires and have study procedures done
* Willingness to belong to either the intervention or standard care arm

Exclusion Criteria:

* FRS \<12% (low risk) -- enrolled into the cohort arm (not randomized. Follow-up at study end only.)
* Any condition that will prevent the patient from participating in and completing the study
* Unable to come to the Group Health Centre for appointments
* Any factor likely to limit protocol compliance
* Unwilling to permit VIP staff to contact their primary physicians to communicate information about the study and the participant's data and treatment assignment
* Previous randomization into this study

Primary outcomes:
measure: The percentage of patients who attained a significant reduction in their global cardiovascular risk at 6 and 12 months. This was determined a priori by the investigators to be an increase in the ACTION Score of 5 or more.
timeFrame: 6 months and 12 months
Secondary outcomes:
measure: Secondary outcomes were change in the average ACTION Score, change in individual risk domains as measured by the ACTION Score, patient satisfaction, and quality of life, all after 6 months and 12 months, comparing intervention versus control.
timeFrame: 6 months and 12 months
Other outcomes:
Locations:
city: Sault Ste. Marie
country: Canada
facility: Group Health Centre
state: Ontario
Study officials:
affiliation: Algoma District Medical Group and Group Health Centre
name: David Crookston, MD CCFP
role: PRINCIPAL_INVESTIGATOR
References: